Debt-free Balance Sheet And Rising Equity/assetsA zero-debt capital structure and rising equity/assets provide durable financial flexibility for a medtech company. This reduces interest burdens, supports funding clinical studies or product development from equity or cash reserves, and lowers insolvency risk during commercialization phases.

Focused Medtech Product Niche (targeted Temperature Management)A focused product portfolio in targeted temperature management gives the company a clear market niche in acute care and therapeutic hypothermia. Specialized clinical applications create higher barriers to entry, enabling durable customer relationships with hospitals and clinicians if product efficacy and support persist.

Multi-year Revenue Scale-up (foundation For Commercialization)Five-year revenue growth from ~7M to ~36M shows prior commercial traction and distribution progress, indicating the business can scale sales. That historical expansion provides a foundation to rebuild growth if unit economics and go-to-market execution improve, making it a durable operational asset.

Bears Say

Negative Gross Profit And Persistent Operating LossesNegative gross profit in 2025 and ongoing operating losses indicate core product economics are currently unfavorable. If unit-level margins remain negative, the business cannot self-sustain through sales growth alone and must materially improve manufacturing, pricing, or product mix to reach durable profitability.

Consistent Cash Burn And Meaningful Negative Free Cash FlowSustained negative operating and free cash flow (≈-56.5M in 2025) creates persistent funding requirements. Reliance on external financing increases dilution and execution risk, and makes long-term product investments conditional on capital access rather than internal cash generation, weakening durability.

Uneven Revenue Trajectory And Recent Y/y DeclineA 17% revenue decline in 2025 after multi-year growth signals volatile demand or execution issues. Unpredictable top-line trends hinder margin leverage, planning for manufacturing and sales investments, and delay reaching scale where fixed costs and R&D amortization improve long-term profitability.

BrainCool AB News

5YL Earnings this Week: How Will it Perform?

BrainCool AB (5YL) is scheduled to report 4th quarter earnings on 02/11/2026. Regarding Q4 estimates, Wall Street analysts...

13d ago

5YL Upcoming Earnings Report: What to Expect?

BrainCool AB (5YL) is scheduled to report 3rd quarter earnings on 11/03/2025. Regarding Q3 estimates, Wall Street analysts...

4M ago

BRAIN FAQ

What was BrainCool AB’s price range in the past 12 months?

BrainCool AB lowest stock price was kr0.42 and its highest was kr2.13 in the past 12 months.

What is BrainCool AB’s market cap?

BrainCool AB’s market cap is kr174.00M.

When is BrainCool AB’s upcoming earnings report date?

BrainCool AB’s upcoming earnings report date is Jun 03, 2026 which is in 102 days.

How were BrainCool AB’s earnings last quarter?

BrainCool AB released its earnings results on Feb 11, 2026. The company reported kr0 earnings per share for the quarter, the consensus estimate of kr0 by kr0.

Is BrainCool AB overvalued?

According to Wall Street analysts BrainCool AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BrainCool AB pay dividends?

BrainCool AB does not currently pay dividends.

What is BrainCool AB’s EPS estimate?

BrainCool AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BrainCool AB have?

BrainCool AB has 337,854,830 shares outstanding.

What happened to BrainCool AB’s price movement after its last earnings report?

BrainCool AB reported an EPS of kr0 in its last earnings report, expectations of kr0. Following the earnings report the stock price went down -3.2%.

Which hedge fund is a major shareholder of BrainCool AB?

Currently, no hedge funds are holding shares in SE:BRAIN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BrainCool AB

BrainCool AB (publ), a medical device company, together with its subsidiaries, engages in the development, marketing, and sale of medical cooling systems for the healthcare sector in Sweden. The company offers products for medical cooling treatments for a range of diseases, including stroke, sudden cardiac arrest, oral mucositis, and migraine. It provides BrainCool and RhinoChill systems that facilitates rapid medical cooling treatment in an emergency setting and ensures the continuum of care; Cooral system provides medical professionals an easy way to reduce the risk of oral mucositis; and IQool system offers an easy-to-use intuitive interface, informative graphics, and an automatic feedback loop allowing clinicians to manage their patient rather than a device. The company was incorporated in 2010 and is based in Lund, Sweden.